UK – New ‘Trojan horse’ cancer treatment shows early promise

A brand new type of cancer drug that acts as a ‘Trojan horse’ to get inside tumour cells has shown promise in patients with six different cancer types.

The innovative new drug, called tisotumab vedotin (TV), releases a toxic substance to kill cancer cells from within. The results have been so positive the drug has now moved forward to phase II trials in cervical cancer and will be tested in a range of additional solid tumour cancers.

A team at The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust led a Phase I/II global clinical trial of nearly 150 patients with a variety of cancer types who had stopped responding to standard treatments and found that a significant minority of cancer patients responded to the drug, with their tumours either shrinking or stopping growing.

They saw responses in 27% of patients with bladder cancer, 26.5% with cervical cancer, 14% ovarian cancer, 13% with oesophageal, 13% with non-small cell lung and 7% with endometrial cancer (although not in any men with prostate cancer)…